Blockchain Registration Transaction Record

Retension Prices $45M Upsized IPO to Advance Hypertension Drug

Retension (NASDAQ: RTSN) prices upsized $45M IPO to fund Phase 2b trial of RTN-001 for uncontrolled hypertension, with shares trading on Nasdaq.

Retension's successful IPO and the funding of its Phase 2b trial for RTN-001 highlight the ongoing need for innovative treatments for uncontrolled hypertension, a condition affecting millions worldwide who do not respond adequately to existing therapies. If RTN-001 proves effective in later-stage trials, it could offer a new option for patients with resistant hypertension, potentially reducing cardiovascular risks and improving outcomes. The listing also provides investors with a new opportunity in the cardiovascular space, where unmet medical needs remain high. Moreover, the involvement of reputable underwriters underscores confidence in the company's approach, which could attract further investment and spur competition in the development of next-generation antihypertensive therapies.